Trial · NCT02844439
Results by group45
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 45
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Efficacy: Median Progression-free Survival (PFS) Rate at 6 Months (PFS-6) | Total | 22.5 | 95% Confidence Interval 10.8 to 38.5 | Percentage (%) of subjects | |
| Efficacy: Median Progression-free Survival (PFS) Rate at 6 Months (PFS-6) | Sub-population A | 25.0 | 95% Confidence Interval 9.8 to 46.7 | Percentage (%) of subjects | |
| Efficacy: Median Progression-free Survival (PFS) Rate at 6 Months (PFS-6) | Sub-population B | 18.2 | 95% Confidence Interval 2.3 to 51.8 | Percentage (%) of subjects | |
| Efficacy: Median PFS | Total | 2.3 | 95% Confidence Interval 1.08 to 2.96 | Months | |
| Efficacy: Median PFS | Sub-population A | 1.7 | 95% Confidence Interval 0.95 to 2.96 | Months | |
| Efficacy: Median PFS | Sub-population B | 1.0 | 95% Confidence Interval 0.92 to 4.93 | Months | |
| Efficacy: Median Overall Survival Rate at 9 Months (OS-9) | Total | 42.5 | 95% Confidence Interval 27.0 to 59.1 | Percentage (%) of subjects | |
| Efficacy: Median Overall Survival Rate at 9 Months (OS-9) | Sub-population A | 37.5 | 95% Confidence Interval 18.8 to 59.4 | Percentage (%) of subjects | |
| Efficacy: Median Overall Survival Rate at 9 Months (OS-9) | Sub-population B | 27.3 | 95% Confidence Interval 6.0 to 61.0 | Percentage (%) of subjects | |
| Efficacy: Median OS | Total | 8.4 | 95% Confidence Interval 7.36 to 12.29 | Months | |
| Efficacy: Median OS | Sub-population A | 7.8 | 95% Confidence Interval 6.64 to 15.67 | Months | |
| Efficacy: Median OS | Sub-population B | 7.6 | 95% Confidence Interval 4.93 to 16.62 | Months | |
| Efficacy: Best Overall Response | Total | CR | 0 | Participants | |
| Efficacy: Best Overall Response | Sub-population A | CR | 0 | Participants | |
| Efficacy: Best Overall Response | Sub-population B | CR | 0 | Participants | |
| Efficacy: Best Overall Response | Total | PR | 1 | Participants | |
| Efficacy: Best Overall Response | Sub-population A | PR | 1 | Participants | |
| Efficacy: Best Overall Response | Sub-population B | PR | 1 | Participants | |
| Efficacy: Best Overall Response | Total | SD | 22 | Participants | |
| Efficacy: Best Overall Response | Sub-population A | SD | 10 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02844439/results